Hypothesis

Increasing circulating carboxylated osteocalcin (cOC) through vitamin K supplementation will reduce hydroxyapatite (HA) crystal size and maturity in bone, thereby enhancing energy dissipation and fracture resistance without necessarily changing bone mineral density (BMD).

Rationale

• Aging bone shows larger, more mature HA crystals that increase brittleness despite higher mineral content[1].
• Simultaneously, age‑related vitamin K deficiency elevates undercarboxylated osteocalcin (ucOC), which binds HA weakly[2] and correlates with poor matrix quality[2]).
• Carboxylated osteocalcin binds HA much more avidly than ucOC[3]], suggesting a direct regulatory role on mineral geometry.
• We propose that cOC’s glutamic acid residues, when carboxylated, act as surface‑specific inhibitors that adsorb to nascent HA faces, suppressing Ostwald ripening and limiting crystal elongation.

Novel Mechanistic Insight

Beyond a passive marker, cOC may function like a biological crystal‑growth modulator: its GLA domains chelate calcium ions on specific crystal planes, increasing the activation energy for further ion addition. This would shift the balance from crystal growth toward nucleation of smaller, more numerous HA particles, improving crack‑deflection and toughness—a property not captured by BMD alone.

Testable Predictions

1. In humans: A 12‑month, double‑blind RCT of vitamin K2 (MK‑7) supplementation in postmenopausal women with low baseline vitamin K status will:
   • Increase serum cOC/ucOC ratio (confirmed by ELISA).
   • Decrease average HA crystal length and width in iliac crest biopsies, measured by synchrotron‑based small‑angle X‑ray scattering (SAXS) or transmission electron microscopy (TEM).
   • Improve bone toughness indices (e.g., post‑yield displacement from reference‑point indentation) without a significant change in BMD (DXA).
2. In vitro: Recombinant cOC added to supersaturated calcium‑phosphate solutions will produce HA precipitates with significantly smaller mean crystal size (<50 nm) compared with ucOC or bovine serum albumin controls, observable via dynamic light scattering and TEM.
3. Ex vivo: Bone strips treated with cOC will exhibit higher energy‑to‑failure in three‑point bending assays than strips treated with ucOC or vehicle, directly linking cOC presence to enhanced mechanical dissipation.

Falsifiability

If vitamin K supplementation fails to alter HA crystal dimensions (as measured by SAXS/TEM) despite raising cOC levels, or if changes in crystal size do not correlate with improved toughness, the hypothesis that cOC directly constrains pathological crystal growth would be refuted. Conversely, observing unchanged crystal size but improved toughness would suggest alternative mechanisms (e.g., collagen cross‑linking) and would also challenge the specific crystal‑size‑mediated pathway.

Implications

Confirming this mechanism would reposition vitamin K not merely as a cofactor for clotting but as a direct modulator of bone material quality, offering a therapeutic avenue to reduce fracture risk in osteoporosis that complements anti‑resorptive or anabolic strategies targeting BMD alone.

References

• [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12343736/
• [2] https://pubmed.ncbi.nlm.nih.gov/9504950/
• [3] https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.669704/full]